Skip to main content
Equibles
INAB logo

INAB · In8bio, Inc. · Metrics

Track INAB — free

Use INAB with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research INAB.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.10 +0.01 (+0.92%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 6, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Based on the Company's business strategy, its existing cash of $18.0 million as of June 30, 2026 is not anticipated to fund the Company's projected operating expenses and capital expenditure requirements for a period of at least 12 months from the date of issuance of these condensed financial statements, and accordingly, there is substantial doubt about the Company's ability to continue to operate as a going concern.”
View the 10-Q filed Aug 6, 2026
Market Cap
$10.75M
Shares
9.86M
Volume · Oct 20 492 Avg daily vol (3M) 54.47K

INAB metrics

52 of 116 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.09
Market cap
$10.75M

Price action

20 metrics
Price change (1W)
-11.4%
Price change (30D)
+2.8%
Price change (3M)
-13.5%
Price change (6M)
-27.3%
Price change (YTD)
-53.4%
Price change (1Y)
-47.3%
Trailing year
Price change (5Y)
—
52-week high
$2.59
52-week low
$0.96
Change from 52-week high
-57.9%
Change from 52-week low
+13.5%
Annualized volatility
85.3%
Annualized volatility (3M)
77.2%
Beta
1.4
RSI (14D)
37.9
Price vs SMA 50
-6.8%
Price vs SMA 200
-28.0%
Avg volume (3M)
54,470
Relative volume
0.4
Average dollar volume
$62,733

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
9.86M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
0.6
reciprocal yield 167.8%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-170.6%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-05-21

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$18.67M
Net income (TTM)
−$18.67M
Trailing 12 months
Diluted EPS (TTM)
$-1.55
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$2.82

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+372.6%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-101.7%
Return on assets
-85.8%
Debt / equity
0.0
Current ratio
8.2
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
8.2
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$18.01M
Latest balance sheet
Cash & equivalents
$18.13M
Total assets
$21.75M
Total debt
$126,000

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$14.36M
Capital expenditures (TTM)
—
R&D (TTM)
$9.86M
SG&A (TTM)
—
Stock compensation (TTM)
$2.16M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
21
13F filer change QoQ
+2
Institutional ownership
38.4%

Ownership (registered funds)

1 metrics
Index-fund ownership
1.7%

Short interest

3 metrics
Short interest
0.5%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
32 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1740279 CUSIP 45674E208 Visit website Investor relations